Headlines
Novo Nordisk membership in UK pharma body restored after suspension
Published by Global Banking & Finance Review®
Posted on March 17, 2025
2 min readLast updated: January 24, 2026
Global Banking & Finance Review®
Company
Published by Global Banking & Finance Review®
Posted on March 17, 2025
2 min readLast updated: January 24, 2026
Novo Nordisk's membership in a UK pharma body is restored after a two-year suspension due to compliance improvements.
By Maggie Fick
LONDON (Reuters) -Danish company Novo Nordisk's membership in a UK pharmaceutical industry body has been restored after a two-year suspension for breaching a national drugmakers practice code.
The Association of the British Pharmaceutical Industry concluded it was satisfied the drugmaker had improved its compliance and governance protocols, the authority said on Monday.
These protocols were audited by the Prescription Medicines Code of Practice Authority, which concluded the company had taken the needed steps to ensure adherence to the code.
The association suspended Novo Nordisk in 2023 for not making clear its involvement in training on obesity drugs that the company offered to pharmacists on social media site LinkedIn.
That year, Novo Nordisk became Europe's most valuable company, surpassing French luxury group LVMH, on the roaring success of its obesity drug Wegovy and diabetes drug Ozempic.
During the audit initiated as a result of the suspension, the PMCPA publicly reprimanded Novo Nordisk twice for further violations of the code, including for failing to properly record and describe payments it made to individuals including patients and journalists.
Novo Nordisk said it had considerably strengthened its compliance processes. "We firmly believe that we now have the right foundations and governance in place to be fully and effectively self-regulating."
(Reporting by Maggie Fick; Editing by Hugh Lawson)
The main topic is Novo Nordisk's restored membership in a UK pharmaceutical body after a suspension for compliance breaches.
Novo Nordisk was suspended for breaching the national drugmakers practice code by not clearly disclosing its involvement in training on obesity drugs.
Novo Nordisk improved its compliance and governance protocols, which were audited and confirmed by the PMCPA.
Explore more articles in the Headlines category
